Form 4: Compass Therapeutics CFO, Barry Shin, Granted Stock Options

Barry Shin, CFO of Compass Therapeutics, was granted stock options to purchase 250,000 shares of common stock.

Summary

• On February 11, 2025, Barry Shin, the CFO of Compass Therapeutics, Inc., was granted stock options.
• These options allow Shin to purchase 250,000 shares of Compass Therapeutics' common stock at an exercise price of $3.65 per share.
• The options vest in 48 substantially equal monthly installments beginning on March 11, 2025, and expire on February 11, 2035.
• The transaction was reported on February 13, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and suggests confidence in the company's future.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes the CFO to remain with the company for the long term.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Regeneron, and Gilead Sciences routinely grant stock options to their executives as part of their overall compensation strategy.
• The size of the grant is typical for a CFO at a company of Compass Therapeutics' size and stage.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the CFO to work towards increasing shareholder value.

Key Dates